TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37106164

Group type: EXPERIMENTAL
Intervention: Subjects without MetS
Number of subjects: 563

Group type: COMPARATOR
Intervention: Subjects with MetS
Number of subjects: 563
Study: 37106206

Group type: EXPERIMENTAL
Intervention: Laparoscopic common bile duct exploration (LCBDE)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Endoscopic retrograde cholangiopancreatography (ERCP)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Laparoscopic common bile duct exploration (LCBDE) failure
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Length of initial stay
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Total length of hospitalization
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Rate of emergency readmissions
Number of subjects: 222
Study: 37106220

Group type: EXPERIMENTAL
Intervention: Mechanical stimulation of the efferent limb with 500 ml of saline chloride solution mixed with a thickening agent (Resource) for 2 weeks before ileostomy reversal.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 0
Study: 37106319

Group type: EXPERIMENTAL
Intervention: M-TAPA block (bupivacaine 0.25%, 25 ml)
Number of subjects: 76

Group type: COMPARATOR
Intervention: OSTAP block (bupivacaine 0.25%, 25 ml)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: M-TAPA block
Number of subjects: 76

Group type: COMPARATOR
Intervention: OSTAP block
Number of subjects: 76
Study: 37106321

Group type: EXPERIMENTAL
Intervention: Early intubation within the first 24 hours of ICU admission
Number of subjects: 4198

Group type: COMPARATOR
Intervention: Late intubation (not explicitly defined in the abstract)
Number of subjects: 4198
Study: 37106343

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (hyperbaric bupivacaine 0.5%)
Number of subjects: 421

Group type: COMPARATOR
Intervention: General anesthesia (intravenous propofol/ketamine/sodium thiopental)
Number of subjects: 421
Study: 37106344

Group type: EXPERIMENTAL
Intervention: Novel anterior nasal swab (ANS)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Combined throat and anterior nasal swab (CTN)
Number of subjects: 249
Study: 37106374

Group type: EXPERIMENTAL
Intervention: Estimated sdLDL-C
Number of subjects: 200

Group type: COMPARATOR
Intervention: Total LDL-C (calculated by Friedewald equation)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Small LDL particles (S-LDLP) and small HDL particles (S-HDLP), along with large and medium TG-rich lipoproteins (TRLPs)
Number of subjects: 200
Study: 37106411

Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 410

Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 410
Study: 37106460

Group type: EXPERIMENTAL
Intervention: Paretic upper limb of stroke patients
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: FuncUseRatio30
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: UseHoursRatio, FuncUseRatio30, JR50
Number of subjects: 30
Study: 37106559

Group type: EXPERIMENTAL
Intervention: Transdiagnostic group cognitive behaviour therapy (CBT)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Diagnosis-specific group cognitive behaviour therapy (CBT)
Number of subjects: 156
Study: 37107208

Group type: EXPERIMENTAL
Intervention: Adherence to a Mediterranean diet (AMD)
Number of subjects: 67
Study: 37107735

Group type: EXPERIMENTAL
Intervention: KiSS intervention arm receiving urge management skills training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 0
Study: 37107844

Group type: COMPARATOR
Intervention: Quartile 4 of Sedentary Time (ST) and ≥300 min/week of Moderate-to-Vigorous Physical Activity (MVPA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Quartile 1 of ST and 150-299 min/week of MVPA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Quartile 1 of ST and 76-149 min/week of MVPA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Quartile 3 of ST and 76-149 min/week of MVPA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Quartiles 1, 2, and 3 of ST with 0-74 min/week of MVPA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Quartile 3 of ST and 150-299 min/week of MVPA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Quartiles 1 and 3 of ST and 76-149 min/week of MVPA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Quartile 1 of ST and 0-74 min/week of MVPA
Number of subjects: 0
Study: 37107849

Group type: EXPERIMENTAL
Intervention: Intervention group (n=564)
Number of subjects: 940

Group type: COMPARATOR
Intervention: Control group (n=376)
Number of subjects: 940
Study: 37107903

Group type: EXPERIMENTAL
Intervention: mHealth interventions (automatic oscillometric device and personalized text messages)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Usual clinical treatment (UCT) without technology
Number of subjects: 231
Study: 37107943

Group type: EXPERIMENTAL
Intervention: Home-based exergame program (balance and lower-extremity muscle strength) for 8 weeks, 50 min three times a week
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Home-based exergame program
Number of subjects: 57
Study: 37108484

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MD), specific details on dosage and duration not available.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weighted gene co-expression network analysis (WGCNA)
Number of subjects: 0
Study: 37109179

Group type: EXPERIMENTAL
Intervention: Auditory steady-state responses (ASSR) and auditory brainstem response (ABR) used to evaluate hearing.
Number of subjects: 50
Study: 37109303

Group type: EXPERIMENTAL
Intervention: Oral sodium-chloride capsules
Number of subjects: 271

Group type: COMPARATOR
Intervention: Intravenous hydration
Number of subjects: 271
Study: 37109468

Group type: EXPERIMENTAL
Intervention: Percutaneous Electrolysis (PE; n = 26)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Deep Dry Needling (DDN; n = 26)
Number of subjects: 52
Study: 37111136

Group type: EXPERIMENTAL
Intervention: Low-dose (LD) supplement containing 440 mg of Fucoxanthin and Guarana
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 61
Study: 37111382

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICIs) treatment
Number of subjects: 276
Study: 37113325

Group type: EXPERIMENTAL
Intervention: Remote home-based upper extremity self-training program
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Motivational interviewing and ecological momentary assessments
Number of subjects: 15
Study: 37113515

Group type: EXPERIMENTAL
Intervention: Aerobic high-intensity interval training (HIT) program for 12 weeks, monitored exercise sessions on treadmill, 4 min × 4 manner, three times a week.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (4 patients)
Number of subjects: 16
Study: 37113674

Group type: EXPERIMENTAL
Intervention: DREAMS 3G (third-generation drug-eluting resorbable magnesium scaffold)
Number of subjects: 116
Study: 37113733

Group type: EXPERIMENTAL
Intervention: Platinum-based chemotherapy
Number of subjects: 150
Study: 37113754

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37114054

Group type: EXPERIMENTAL
Intervention: Camrelizumab plus platinum-irinotecan (IP/IC)
Number of subjects: 53

Group type: COMPARATOR
Intervention: EP/EC plus PD-L1 inhibitor (historical control)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Immune-related adverse events in IP/IC plus camrelizumab group
Number of subjects: 53
Study: 37114393

Group type: EXPERIMENTAL
Intervention: Novel prognostic index combining baseline metabolic tumour volume (MTV) with clinical and pathological parameters.
Number of subjects: 289

Group type: COMPARATOR
Intervention: Ann Arbor staging and NCCN-IPI (as control for comparison).
Number of subjects: 289
Study: 37114918

Group type: EXPERIMENTAL
Intervention: Autologous Fat Transfer (AFT)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Implant-Based Reconstruction (IBR)
Number of subjects: 46
Study: 37114990

Group type: EXPERIMENTAL
Intervention: KCCQ-12 (Kansas City Cardiomyopathy Questionnaire-12)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: KCCQ-12
Number of subjects: 21
Study: 37115054

Group type: EXPERIMENTAL
Intervention: Pregabalin sustained-release (SR) tablet (150 mg once a day)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Pregabalin immediate-release (IR) capsule (75 mg twice a day)
Number of subjects: 130
Study: 37115132

Group type: EXPERIMENTAL
Intervention: No-implant interatrial shunt
Number of subjects: 28
Study: 37115135

Group type: EXPERIMENTAL
Intervention: Guideline-directed medical therapy (GDMT)
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: ACEIs/ARBs/ARNIs
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: MRAs
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Goal doses of beta-blockers
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Goal doses of ACEIs/ARBs/ARNIs
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: All 3 GDMT classes
Number of subjects: 464
Study: 37115167

Group type: EXPERIMENTAL
Intervention: Appropriate shocks delivered for ventricular fibrillation (VF) or wide complex rhythms ≥ 150/min
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Indeterminate shocks (narrow complex ≥ 150/min or wide complex 100-149/min)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Inappropriate shocks delivered for asystole, sinus, narrow complex < 150/min, or wide complex < 100/min
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Shocks delivered in ICUs or emergency departments
Number of subjects: 159
Study: 37115337

Group type: EXPERIMENTAL
Intervention: COVID-19 patients
Number of subjects: 54

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 54
Study: 37115359

Group type: EXPERIMENTAL
Intervention: Ataluren plus standard of care (SoC)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Standard of care (SoC) alone
Number of subjects: 307
Study: 37115464

Group type: EXPERIMENTAL
Intervention: Mirogabalin 5-10 mg BID for 4 weeks, then 15 mg BID for 47 weeks, followed by tapering to once daily for 1 week.
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Mirogabalin treatment for CNePSCI, CPSP, and CNePPD.
Number of subjects: 210
Study: 37115514

Group type: EXPERIMENTAL
Intervention: Selumetinib (continuous dosing, 1 cycle = 28 days)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Selumetinib (continuous dosing)
Number of subjects: 74
Study: 37115541

Group type: COMPARATOR
Intervention: DVD intervention
Number of subjects: 963

Group type: COMPARATOR
Intervention: DVD/PN intervention
Number of subjects: 963

Group type: COMPARATOR
Intervention: DVD group
Number of subjects: 963

Group type: COMPARATOR
Intervention: DVD/PN group
Number of subjects: 963

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 963
Study: 37115590

Group type: EXPERIMENTAL
Intervention: Place-Based Permanent Supportive Housing (PB-PSH)
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Scatter-Site Permanent Supportive Housing (SS-PSH)
Number of subjects: 563
Study: 37115610

Group type: EXPERIMENTAL
Intervention: Behavioral economics-based incentives with anchoring strategy for meditation adherence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-monitoring messages for meditation tracking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Financial incentives for meditation at any time of day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Financial incentives for meditation performed at approximately the same time of day as personalized anchors
Number of subjects: 0
Study: 37115620

Group type: EXPERIMENTAL
Intervention: Scheduled coaching calls and gamified rewards
Number of subjects: 200

Group type: COMPARATOR
Intervention: No scheduled coaching calls and gamified rewards
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Scheduled coaching calls and flat rewards
Number of subjects: 200

Group type: COMPARATOR
Intervention: No scheduled coaching calls and flat rewards
Number of subjects: 200
Study: 37115632

Group type: EXPERIMENTAL
Intervention: Aquablation procedure
Number of subjects: 101
Study: 37115658

Group type: EXPERIMENTAL
Intervention: FAITH! Hypertension App
Number of subjects: 16
Study: 37115724

Group type: COMPARATOR
Intervention: Personalised intervention
Number of subjects: 858
Study: 37115807

Group type: EXPERIMENTAL
Intervention: Bruton's tyrosine kinase (BTK) and a proliferation-inducing ligand (APRIL) genes overexpression in patients with incident lymphoma (i-primary SS-NHL)
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Bruton's tyrosine kinase (BTK) expression
Number of subjects: 345

Group type: COMPARATOR
Intervention: Transcriptomic analysis of 21 patients with primary SS-NHL
Number of subjects: 345
Study: 37115905

Group type: EXPERIMENTAL
Intervention: INSTI-based first prescribed regimen
Number of subjects: 9094

Group type: EXPERIMENTAL
Intervention: First ART discontinuation and reaching a first undetectable pVL
Number of subjects: 9094
Study: 37115908

Group type: EXPERIMENTAL
Intervention: Standard medical therapy plus growth hormone (GH) therapy
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard medical therapy alone
Number of subjects: 76
Study: 37115976

Group type: EXPERIMENTAL
Intervention: Anti-SARS-CoV-2 vaccination
Number of subjects: 809

Group type: EXPERIMENTAL
Intervention: Survey on pandemic burden and vaccination hesitancy
Number of subjects: 809
Study: 37116052

Group type: EXPERIMENTAL
Intervention: Traumatic life events and stressors
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Depression and anxiety of men under community supervision
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Partner's substance use problems
Number of subjects: 230
Study: 37116057

Group type: EXPERIMENTAL
Intervention: Photobiomodulation Therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37116228

Group type: EXPERIMENTAL
Intervention: Kukoamine B (KB) at doses of 0.06, 0.12, or 0.24 mg/kg every 8 hours for 7 days
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Kukoamine B (KB)
Number of subjects: 44
Study: 37116523

Group type: EXPERIMENTAL
Intervention: Quizartinib plus chemotherapy
Number of subjects: 539

Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Quizartinib
Number of subjects: 539

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 539
Study: 37116605

Group type: EXPERIMENTAL
Intervention: NT-proBNP levels measured on days 0, 1, 2, 3, and 7
Number of subjects: 1105

Group type: EXPERIMENTAL
Intervention: NT-proBNP levels on days 2, 3, and 7
Number of subjects: 1105
Study: 37116644

Group type: EXPERIMENTAL
Intervention: 10-week group-based intervention
Number of subjects: 360

Group type: COMPARATOR
Intervention: Standard group-delivered PA comparison program
Number of subjects: 360
Study: 37116645

Group type: EXPERIMENTAL
Intervention: SHARE intervention (multicomponent communication intervention)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Minimally enhanced usual care (control)
Number of subjects: 248
Study: 37116657

Group type: EXPERIMENTAL
Intervention: Glycomacropeptide (GMP) supplementation
Number of subjects: 13
Study: 37116658

Group type: EXPERIMENTAL
Intervention: TX Sprouts intervention (gardening, cooking, and nutrition education)
Number of subjects: 468

Group type: COMPARATOR
Intervention: Control (delayed intervention)
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: TX Sprouts intervention (gardening, cooking, and nutrition education) among Hispanic children
Number of subjects: 468
Study: 37116714

Group type: EXPERIMENTAL
Intervention: 'One-stop-shop' point-of-care HCV RNA testing intervention
Number of subjects: 540

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 540
Study: 37116746

Group type: EXPERIMENTAL
Intervention: Nerve-sparing laparoscopic resection for RSE
Number of subjects: 3050
Study: 37116825

Group type: EXPERIMENTAL
Intervention: Curcumin (600 mg Theracurmin HP daily for 30 days)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo (daily for 30 days)
Number of subjects: 58
Study: 37116952

Group type: EXPERIMENTAL
Intervention: Comprehensive staging surgery without lymphadenectomy
Number of subjects: 656

Group type: COMPARATOR
Intervention: Completion staging surgery including systematic pelvic and para-aortic lymphadenectomy
Number of subjects: 656
Study: 37116972

Group type: EXPERIMENTAL
Intervention: isCGM
Number of subjects: 945
Study: 37117001

Group type: EXPERIMENTAL
Intervention: 3-month multidomain intervention programme including cognitive training, physical exercise, nutrition, psychoeducation, and assessment/correction of hearing loss.
Number of subjects: 70

Group type: COMPARATOR
Intervention: Usual standard of care provided to these diseases.
Number of subjects: 70
Study: 37117085

Group type: EXPERIMENTAL
Intervention: Percutaneous intervention (CTO-PCI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pharmaceutical therapy
Number of subjects: 0
Study: 37117153

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 3067

Group type: EXPERIMENTAL
Intervention: Pulse pressure
Number of subjects: 3067

Group type: EXPERIMENTAL
Intervention: Uric acid
Number of subjects: 3067

Group type: EXPERIMENTAL
Intervention: Glycosylated haemoglobin (HbA1c)
Number of subjects: 3067

Group type: EXPERIMENTAL
Intervention: Lipoprotein(a)
Number of subjects: 3067

Group type: EXPERIMENTAL
Intervention: High-density lipoprotein cholesterol (HDL-C)
Number of subjects: 3067

Group type: EXPERIMENTAL
Intervention: Prediction model including risk factors
Number of subjects: 3067
Study: 37117201

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 13

Group type: COMPARATOR
Intervention: Individualized relapse-based approach
Number of subjects: 13
Study: 37117213

Group type: EXPERIMENTAL
Intervention: MasitinibL
Number of subjects: 0

Group type: COMPARATOR
Intervention: Masitinib
Number of subjects: 0
Study: 37117993

Group type: EXPERIMENTAL
Intervention: Model combining tau phosphorylated at threonine 181 (P-tau181) and neurofilament light (NfL)
Number of subjects: 573

Group type: COMPARATOR
Intervention: Plasma biomarkers of β-amyloid (Aβ)
Number of subjects: 573
Study: 37118058

Group type: EXPERIMENTAL
Intervention: Tryptophan (TRYP) 6g
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 37118158

Group type: EXPERIMENTAL
Intervention: Standard Volar Approach (SVA)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Pronator-Sparing Approach (PqSA)
Number of subjects: 106
Study: 37118334

Group type: EXPERIMENTAL
Intervention: Partially de-epithelialized free gingival grafts (d-FGGs)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Conventional free gingival grafts (FGGs)
Number of subjects: 15
Study: 37118696

Group type: EXPERIMENTAL
Intervention: Cough desensitization treatment (CDT)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 21
Study: 37118703

Group type: EXPERIMENTAL
Intervention: Elevated cTnT (≥ 14 ng/L) one year after the primary event
Number of subjects: 1278

Group type: COMPARATOR
Intervention: Low cTnT after the primary event
Number of subjects: 1278
Study: 37118707

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 30

Group type: COMPARATOR
Intervention: Triamcinolone injection
Number of subjects: 30
Study: 37118803

Group type: EXPERIMENTAL
Intervention: Furmonertinib 40 mg orally once daily
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Furmonertinib 80 mg orally once daily
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Furmonertinib 160 mg orally once daily
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Furmonertinib 240 mg orally once daily
Number of subjects: 132
Study: 37118818

Group type: EXPERIMENTAL
Intervention: Total thyroidectomy with bilateral prophylactic central neck dissection and adjuvant RAI 30 mCi
Number of subjects: 598

Group type: COMPARATOR
Intervention: Total thyroidectomy alone
Number of subjects: 598
Study: 37118832

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cell (BMMNC) infusion
Number of subjects: 11
Study: 37118904

Group type: EXPERIMENTAL
Intervention: Telomere-Shortest-Length-Assay (TeSLA)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Southern blotting (SB)
Number of subjects: 352
Study: 37119051

Group type: EXPERIMENTAL
Intervention: Enzalutamide (enza) + Leuprolide Acetate (LA) 160 mg/day
Number of subjects: 1068

Group type: EXPERIMENTAL
Intervention: Enzalutamide monotherapy (mono)
Number of subjects: 1068

Group type: COMPARATOR
Intervention: Placebo + Leuprolide Acetate (LA)
Number of subjects: 1068
Study: 37119056

Group type: EXPERIMENTAL
Intervention: SAR445088 in SOC-Treated group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: SAR445088 in SOC-Refractory group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: SAR445088 in SOC-Naïve group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: SAR445088 during 12-week overlapping period in SOC-Treated group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: SAR445088 in Part B
Number of subjects: 90
Study: 37119064

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 4304

Group type: COMPARATOR
Intervention: Control (no dapagliflozin)
Number of subjects: 4304
Study: 37119067

Group type: EXPERIMENTAL
Intervention: Direct Oral Anticoagulants (DOACs)
Number of subjects: 5231

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 5231

Group type: EXPERIMENTAL
Intervention: Aortic Stenosis (AS)
Number of subjects: 5231
Study: 37119080

Group type: EXPERIMENTAL
Intervention: High platelet reactivity (HPR) on clopidogrel (≥252 P2Y12 reactivity units) in men
Number of subjects: 11714

Group type: EXPERIMENTAL
Intervention: High platelet reactivity (HPR) on clopidogrel (≥252 P2Y12 reactivity units) in women
Number of subjects: 11714

Group type: COMPARATOR
Intervention: Control group (men without HPR)
Number of subjects: 11714

Group type: COMPARATOR
Intervention: Control group (women without HPR)
Number of subjects: 11714
Study: 37119085

Group type: EXPERIMENTAL
Intervention: Cardiovascular magnetic resonance assessment
Number of subjects: 2175

Group type: EXPERIMENTAL
Intervention: Temporary acute kidney injury (AKI)
Number of subjects: 2175
Study: 37119094

Group type: EXPERIMENTAL
Intervention: Stellate ganglion block (SGB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-SGB (control group)
Number of subjects: 0
Study: 37119097

Group type: EXPERIMENTAL
Intervention: ICPinf monitoring
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: ICPinf burden
Number of subjects: 15

Group type: COMPARATOR
Intervention: ICPsup
Number of subjects: 15